Clinical Trial Update: Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating binimetinib in combination with imatinib for unresectable KIT-mutant melanoma (Stage III-IV) is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Binimetinib (binimetinib)
• Imatinib (imatinib)

Snippet

Sponsor: University of California, San Francisco | Conditions: Melanoma Stage III, Melanoma Stage IV | Phase 2 | Status: RECRUITING